2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Transfusion, Non-Biological Therapies, Devices, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Computer Vision, Machine Learning, Biological Processes, Genomics, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Quality of Care, Systems-Based Hematology, Value, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Infectious Diseases, Viral, Bacterial, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Embryo/Fetus, Pediatric, Pregnant, Young Adult
PAPER

1189 Breastfeeding in mothers with sickle cell disease: Association with postpartum outcomes

Nawras Zayat, MD, Jared Eckman, MD2, Rachael Bertuzzi, NP3, Henny H. Billett, MD4
1 Montefiore-Einstein Medical Center, Bronx, New York, United States
2 Montefiore-Einstein Medical Center, Bronx, New York, United States
3 Montefiore EInstein Medical Center, Bronx, New York, United States
4 Montefiore EInstein Medical Center, Bronx, New York, United States

Background: 
Pregnancy in sickle cell disease (SCD) is associated with substantial maternal and neonatal morbidity. However, breastfeeding patterns and postpartum outcomes in this population remain incompletely characterized. We investigated initiation and persistence of breastfeeding and the relationship to transfusion burden, maternal morbidity, and neonatal outcomes, among women with SCD. 

Methods: 
We conducted an ambispective cohort study of 39 deliveries among patients with confirmed SCD at a large urban academic medical center between 2015 and 2026. Maternal hematologic, obstetric, transfusion, breastfeeding, and neonatal outcomes were abstracted from the electronic medical record. 

Results: 
Thirty-nine (39) deliveries among 30 patients met inclusion criteria. HbSS was the predominant genotype (21 patients; 25 deliveries), followed by  HbSC  (5 patients; 8 deliveries), HbSβ°-thalassemia (2 patients; 3 deliveries), HbS/HPFH  (1 patient; 1 delivery), and  HbSβ?-thalassemia (1 patient; 2 deliveries). Median maternal age was 29.2 years (IQR: 25.7-31.9), median pre-pregnancy BMI was 24.3 kg/m² (IQR: 22.6-28.9), and median admission hemoglobin was 8.3 g/dL (IQR: 7.4-9.0). Nineteen (19) women self-identified as Black/Non-Hispanic; 2 as Black/Hispanic; 1 as Black/declined to answer; 7 as Other/Hispanic; 1 declined to answer race or ethnicity.

Transfusion exposure was substantial throughout pregnancy and the postpartum period. Among patients with available data, 28/38 (73.7%) received transfusions during pregnancy, with incident simple transfusions as the majority. Fourteen of 39 (35.9%) received transfusion(s) during the delivery admission, all within the first postpartum week. Postpartum hemorrhage >500 mL occurred in 14/39 deliveries (35.9%), including 5/39 (12.8%) with hemorrhage >1000 mL. Preeclampsia complicated 12/39 pregnancies (30.8%). Significant morbidity persisted after delivery, with 5/35 patients (14.3%) requiring readmission within 6 weeks postpartum, most commonly for vaso-occlusive crisis or acute chest syndrome. No maternal deaths occurred. 

Many of the deliveries were complicated by neonatal morbidity. Median gestational age at delivery was 38w1d (IQR: 36w4d-39w1d), with preterm birth <37 weeks occurring in 12/39 deliveries (30.8%), including 7/39 (17.9%) before 34 weeks. Thirteen of 39 neonates (33.3%) were small for gestational age, and NICU admission occurred in 15/39 neonates (38.5%). One neonatal death occurred following delivery at 26 weeks gestation, yielding neonatal survival of 97.4%. 

Breastfeeding intention was high (33/34, 97.1%), and breastfeeding was documented in 34/39 deliveries (87.2%) at discharge. However, persistence declined to 24/35 (68.6%) at 6 weeks and 11/35 (31.4%) at approximately 6 months postpartum. Compared with published U.S. population data among non-Hispanic Black women (~79% breastfeeding at 8 weeks postpartum), breastfeeding persistence appeared lower in this SCD cohort. While breastfeeding rates at discharge were similar regardless of NICU admission, long-term persistence was markedly lower among patients whose infants required NICU admission (7.1% vs 47.6%). Patients with admission hemoglobin <8g/dl demonstrated lower breastfeeding rates at 6 weeks postpartum (63.6% vs 94.1%), and patients with higher disease severity had lower breastfeeding persistence at 6 weeks (50% vs 77% in moderate-severity disease) and greater transfusion burden. 

Conclusions: Women with SCD experience substantial hematologic morbidity extending beyond delivery, characterized by frequent transfusion requirements, postpartum complications, and early readmissions. Although breastfeeding initiation is high, persistence declines substantially over time and appears lower than reported population rates, particularly among patients with NICU admission and markers of more severe disease. These findings support integrated hematology-obstetric care models extending into the postpartum period to address ongoing maternal and neonatal risk. 

Jared Eckman, MD: No relevant conflicts of interest to declare.